Last edition
News about "aflibercept biosimilar"
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili
Biocon has published pivotal clinical data supporting the effectiveness of Yesafili, its Food and Drug Administration (FDA)-approved interchangeable aflibercept biosimilar, demonstrating comparable safety, efficacy, and immunogenicity.
Aflibercept Biosimilar | 09/07/2026 | By News Bureau | 111
Teva Pharma Launches AHZANTIVE Biosimilar to Eylea in Europe
Teva has launched AHZANTIVE (aflibercept), an EMA-approved biosimilar to Eylea, across Europe. Demonstrating comparable efficacy, safety, and immunogenicity to the reference product, the launch expands Teva’s biosimilars and ophthalmology portfolio while supporting its long-term Pivot to Growth strategy.
Aflibercept Biosimilar | 06/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy